Trials / Completed
CompletedNCT05421338
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
A Phase I, Open-label, Single-dose, Single-arm Trial to Investigate Metabolism and Pharmacokinetics of BI 456906 (C-14) Administered Subcutaneously to (Otherwise) Healthy Male Volunteers With Normal Body Weight, Overweight or Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This trial is intended to examine the basic pharmacokinetics of BI 456906 and total \[14C\]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in (otherwise) healthy male volunteers with normal body weight, overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 456906 (C-14) | BI 456906 (C-14) |
Timeline
- Start date
- 2022-07-04
- Primary completion
- 2022-11-17
- Completion
- 2022-11-17
- First posted
- 2022-06-16
- Last updated
- 2022-12-14
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05421338. Inclusion in this directory is not an endorsement.